|
 
 |
| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 4
| Issue : 2 | Page : 65-77 |
|
Pathogenesis of vitiligo: An update
Amanjot K Arora, Muthu S Kumaran
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| Date of Web Publication | 1-Dec-2017 |
Correspondence Address:
Muthu S Kumaran
Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Sector-12, Chandigarh - 160 012
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2349-5847.219673
Vitiligo is the most common depigmentary disorder that has been affecting human lives across centuries. Despite its high prevalence, not much can be said precisely about its pathogenesis. Over the years, several theories based on a lot of research have been put forward and many more are coming up each day. This article aims to summarise the various theories put forward so far and highlight the Recent updates in each of them.
Keywords: Pathogenesis, update, vitiligo
How to cite this article:
Arora AK, Kumaran MS. Pathogenesis of vitiligo: An update. Pigment Int 2017;4:65-77 |
| Introduction | |  |
Vitiligo is a commonly acquired depigmentary disorder of skin, also known as swetakusta in Indian literature. Clinically, it is characterized by development of depigmented macules and patches secondary to selective destruction of melanocytes.[1] Clinically, two major subtypes of vitiligo are well recognized: non-segmental and segmental. Non-segmental vitiligo (NSV) is the more common subtype, having asymmetrical, non-dermatomal distribution usually with a gradual onset.[2] Segmental vitiligo (SV) is less common and is characterized by a unilateral dermatomal distribution which usually has an early rapid onset and stabilizes in a limited location once fully developed.[2] The prevalence of vitiligo is high ranging from 0.005 to 0.38% cases worldwide.[3],[4],[5] Gujarat, located on the western coast of the Indian Peninsula, has been reported to have a prevalence of 8.8%, the highest in the world.[5],[6] Despite its high prevalence and old history, its etiopathogenesis is complex and enigmatic. Most of the currently available evidence supports the occurrence of an autoimmune phenomenon in patients with an underlying genetic predisposition.[7] However, with further advancement and research in understanding the pathogenesis of this psychologically devastating disease, newer insights into its etiopathogenesis keep emerging.
For this review, we searched PubMed, Google and Google Scholar with keywords including ‘vitiligo’, ‘pathogenesis’, ‘vitiligo pathogenesis latest’, ‘epidemiology’ and ‘etiopathogenesis’. All types of studies including reviews, in vivo / in vitro experimental studies, animal studies and observational studies published in standard peer-reviewed journals were included. This review aims to discuss the various known as well as newer emerging theories in the pathogenesis of vitiligo. To make the review more interesting, the data until 2011 has been placed under ‘What is known’ category, and the data from studies published in the last 5 years has been placed under the ‘Recent updates’ category. Because NSV is a more common form of vitiligo, most of the experimental studies and theories discussed in this review pertain to pathogenesis of NSV. However, wherever a difference in the pathogenesis of the two types as been suggested in literature, a mention has been made in the text.
Genetics
What is known?
Familial clustering is seen in vitiligo. Various studies have found that the frequency of vitiligo among first-degree relatives varies from 0.14% to as high as 20%.[8],[9],[10] Such figures suggest a definite genetic component. Nevertheless, only 23% concordance has been observed amongst monozygotic twins, which suggests that a significant non-genetic component exists in the pathogenesis of vitiligo.[8] As vitiligo is a polygenic disease, several candidate genes including major histocompatibility complex (MHC), angiotensin-converting enzyme (ACE), catalase (CAT), cytotoxic T lymphocyte antigen-4 (CTLA-4), catechol-O-methyltransferase (COMT), estrogen receptor (ESR), mannan-binding lectin (MBL2), protein tyrosine phosphatase, non-receptor type 22 (PTPN22), human leukocyte antigen (HLA), NACHT leucine-rich repeat protein 1 (NALP1), X-box binding protein 1 (XBP1), forkhead box P1 (FOXP1) and interleukin-2 receptor A (IL-2RA), that are involved in the regulation of immunity have been tested for genetic association with generalized vitiligo.[11],[12] In patients with various vitiligo-associated autoimmune/auto-inflammatory syndromes, HLA haplotypes, especially HLA-A2, −DR4, −DR7 and −DQB1*0303, have been frequently found to play an important role[13],[14] At the same time, in patients with vitiligo alone, PTPN22, NALP1 and XBP1 have been found to play a causal role.[15],[16],[17]
Genome-wide linkage analysis has revealed autoimmune susceptibility (AIS) loci associated with vitiligo. AIS1 was discovered to be located on chromosome 1p31.3–p32.2,[18] AIS2 on chromosome 7 and AIS3 on chromosome 8.[19] AIS1 and AIS2 linkages were found to occur in families with vitiligo along with other autoimmune diseases, while AIS3 was found in the non-autoimmune family subgroup. Another gene, that is, systemic lupus erythematosus vitiligo-related gene (SLEV1) located on chromosome 17, was found to be associated with generalized vitiligo present in association with other concomitant autoimmune diseases.[19]
Recent updates
In a recent study, gene expression profiling was performed in patients with SV and NSV to analyze the changes in gene expression in patients with vitiligo and compare the two groups with each other as well as healthy individuals (HI).[20] High-throughput whole genome expression microarrays were used to assay the gene expression profiles among HI, SV and NSV. In this study, they found that in patients with SV with HI as a control, the differently expressed genes included the ones involved in the adaptive immune response, cytokine–cytokine receptor interaction, chemokine signalling, focal adhesion and sphingolipid metabolism. On the other hand, the differently expressed genes in patients with NSV mainly controlled the innate immune system, autophagy, apoptosis, melanocyte biology, ubiquitin-mediated proteolysis and tyrosine metabolism. Thus, they concluded that different genetic patho-mechanisms were involved in the two distinct subtypes of vitiligo. In another study from China, the C allele of rs35652124 located on the promoter region of nuclear factor E2-related factor 2 (Nrf2) gene was found to have a protective effect against vitiligo.[21] Lately, the role of microRNAs (miRNAs) and toll-like receptors (TLRs) in the pathogenesis of vitiligo has been explored.[22],[23] In a study by Šahmatova et al., miR-99b, miR-125b, miR-155 and miR-199a-3p levels were found to be increased while that of miR-145 was found to be decreased in the skin of patients with vitiligo. MiRNAs (miR-155) when over-expressed lead to the inhibition of melanogenesis-associated genes and altered interferon-regulated genes in the melanocytes and keratinocytes.[22] Traks et al. recently established the role of TLRs and vilitgo in their study, wherein they found that single nucleotide polymorpisms (SNPs) in TLR7 were associated with vitiligo making them a future target for targeted therapies.[23] Recently, Shen et al. also reviewed the various key loci that have been implicated in the pathogenesis of vitiligo, and interested readers can refer them.[24] Thereupon, the data available so far suggest that vitiligo has a polygenic inheritance with no single gene dictating its pathogenesis.
| Autoimmune hypothesis | | |
Autoimmunity has long been suspected to play a significant role in the pathogenesis of vitiligo. This has been substantiated by multiple studies published in the literature so far. Both cellular and humoral immunity have been found to be of etiological significance in the pathogenesis of vitiligo.
Cellular Immunity
What is known?
As far as cellular immunity is concerned, the main culprits are the CD8+ cytotoxic T-cells. Perilesional skin biopsies have shown epidermotropic cutaneous lymphocyte antigen positive lymphocytes with an increased CD8+/CD4+ ratio, substantiating the role of cytotoxic T-cells in the pathogenesis of vitiligo.[25],[26] These T-cells have been shown to bring about degenerative changes in melanocytes and vacuolization of basal cells in the normal-appearing perilesional skin in patients with actively spreading lesions.[27] An increased expression of CD25 and MHC II (specifically HLA-DR) and ability to secrete interferon gamma (IFN γ) has been noted in these T-cells which lead to increased expression of intercellular adhesion molecule-1 and, consequently, increased T-cell migration to the skin leading to a vicious cycle.[25],[26]
Also, high frequencies of Melan-A-specific CD8+ T-cells have been found in patients with vitiligo, and their number may correlate with disease extent.[28],[29],[30] Another subset of T-cells, called the follicular T helper (Tfh) cells, has been described lately in the pathogenesis of vitiligo.[31],[32] The Tfh cells secrete interleukin (IL) 21 IL-21 which brings about B-cell activation, thereby, playing a pivotal role in autoimmune diseases such as vitiligo. They are also key players in cytotoxic responses as they promote an increase in CD8+ T-cells and prolong their cytotoxic responses.[31],[32]
Recent updates
Interferon γ (IFN γ) has been recently identified as a part of the ‘signature cytokine profile’ implicated in the pathogenesis of vitiligo. In an engineered mouse model of vitiligo, Harris and co-workers found IFNs to play a central role in the spread of vitiligo lesions by bringing about an increased expression of CXCL10, which subsequently regulates the invasion of epidermal and follicular tissues by CD8+ T-cells.[33] Similar results were seen in an avian model, in which an increased expression of IFN γ correlated well with the progression of vitiligo.[34]
IL-17 and T helper type 17 (Th17) cells, which elaborate this cytokine, have been increasingly recognized to play an important role in autoimmunity. Singh et al. recently reviewed their role in vitiligo and found increased levels of IL-17 in the blood as well as the tissue samples of patients with vitiligo.[35] These findings were further substantiated by Zhou et al.[36] and Bharadwaj et al.,[37] who found that the levels of Th17 cells correlated well with disease activity in generalized vitiligo. The latter also found significant increase in the expression of IL-1β and transforming growth factor-beta (TGF-β) in patients with active NSV.[37]
In a recent study, serum levels of IL-33 were found to be significantly increased in patients with vitiligo and showed positive correlation with disease activity. This study suggested a possible etiologic role of IL-33 in the pathogenesis of vitiligo and concluded it to be a target for future therapies.[38]
In recent times, various studies have highlighted the pivotal role of regulatory T-cells (Tregs) in the pathogenesis of vitiligo.[39] Tregs are known to fight against autoimmunity and their levels have been reported to be lower in patients with vitiligo,[40],[41] especially, in the lesional and perilesional skin.[42] Not only are they decreased in number but they also have impaired functioning.[39] Both TGF-β and IL 10, which are physiological inducers of Tregs, have been found to be decreased in active vitiligo lesions.[43],[44]
Humoral Immunity
What is known?
Various subsets of antibodies are seen in patients with vitiligo and are categorized as those against cell surface pigment cell antigens, intracellular pigment cell antigens and non-pigment cell antigens.[45] Certain antigens namely VIT 40/75/90, named after their respective weights, have been identified in around 83% patients with vitiligo. Although VIT 90 is found exclusively on pigment cells, VIT 40 and VIT 75 are considered common to both pigment and non-pigment cells. Non-specific antibodies against these antigens have been found in patients with vitiligo.[46] As melanocytes are much more sensitive to immune-mediated injury, it is probable that minimal injury from non-specific antibodies may induce lethal harm to melanocytes, but not to the surrounding cells.[47] Antibodies against tyrosinase and tyrosinase-related proteins 1 and 2 (TRP-1 and TRP-2), SOX9 and SOX 10 (transcription factors involved in the differentiation of cells derived from the neural crest) have also been detected in patients with autoimmune polyendocrine syndrome type 1 (APS1) and in patients with vitiligo without any concomitant disease.[48],[49],[50]
Recent updates
In a recent study, 15 out of 19 patients with unstable vitiligo were found to be positive for antibodies against melanocytes.[51] Anti-melanocyte antibodies have been found to localize in the cytoplasm of melanocytes.[52] In another study, antibodies against membrane and cytoplasmic antigens were discovered in patients with vitiligo and, using protein mass spectrometry, these membrane antigens were identified to be Lamin A/C and Vimentin X.[52] Thus, the role of anti-melanocyte antibodies in the pathogenesis of vitiligo cannot be refuted.
Oxidative stress
What is known?
The oxidative stress theory of vitiligo suggests that the main culprit in the pathogenesis of vitiligo is the intra-epidermal accumulation of reactive oxygen species (ROS), the most notorious of which is H2O2 whose concentration may reach upto one milimole.[53],[54],[55] At this concentration, H2O2 leads to changes in the mitochondria and, consequently, apoptosis/death of the melanocytes.[56],[57]
Alterations in the markers of redox status are commonly seen in patients with vitiligo.[58] Important markers of interest are malondialdehyde (MDA), selenium, vitamins, glutathione peroxidase (GPx), superoxide dismutase (SOD) and CAT.[58],[59] MDA is a product of lipid peroxidation and an indicator of oxidative stress.[58],[59] Selenium is required for GPx activity and is a major antioxidant present in the erythrocytes. SOD scavenges superoxide radicals and reduces their toxicity (converts O2– to O2 and H2O2), and CAT converts H2O2 to O2 and H2O.[58],[59] Significantly higher levels of SOD, decreased erythrocyte GPx activity, low levels of enzyme CAT and vitamins C and E have been detected both in the epidermis and in the serum of patients with vitiligo[60],[61],[62],[63] Ines et al. found that SOD activity was increased in both stable and active disease, while MDA and selenium levels were increased most notably in active disease only. The erythrocyte CAT activity and serum vitamin A and E levels were not significantly different from controls.[64] The researchers insisted that enhanced SOD activity could result in the accumulation of H2O2. Additionally, CAT and GPx are downstream enzymes that detoxify H2O2, and GPx levels were found to be lower in patients with vitiligo, thereby, compounding H2O2 accumulation.[64] In a later study, it was found that SOD, GPx and MDA levels were increased in active and stable disease jointly, with higher increases consistently present in the active group. On the contrary, CAT activity was notably more decreased in the active group than in stable disease.[65] The authors suggested that increase in SOD activity ultimately resulted in H2O2 accumulation (as it catalyses a reversible reaction) that is not broken down by CAT, because its levels are lower than normal.[65]
SNPs interfering with the CAT enzyme’s subunit assembly and function, have been found more frequently in patients with vitiligo.[66] In addition, H2O2 accumulation brings about degradation of the active site of CAT enzyme, thereby making it unsuitable to function.[67] Furthermore, deranged melanin synthesis pathways involving 6-biopterin lead to increased synthesis of ROS and subsequent oxidative injury to melanocytes.[68],[69],[70]
A new theory, called the haptenation theory, has been proposed to establish the pathogenic role of oxidative stress in vitiligo.[71] According to this hypothesis, high levels of H2O2 lead to increased levels of tyrosinase enzyme and its activity which, because of a genetic polymorphism specific to ‘vitiligo’ melanocytes, is capable of binding to a variety of substrates such as noradrenalin (during severe mental stress and bereavement), tri-iodothyronine and estrogen, thereby, generating orthoquinone metabolites. These metabolites act as putative haptogenic substrates for tyrosinase and convert the tyrosinase enzyme into a neoantigen, which eventually acts as an autoantigen for the immune system.[71] Thus, an autoimmune reaction is triggered which brings about depigmentation by selective destruction of melanocytes containing the autoantigen in the form of altered tyrosinase enzyme.[71]
Recent updates
In a recent study, Zalaie contradicted the aforementioned findings by spectrometrically measuring H2O2 in the lesional and non-lesional skin of patients with vitiligo of skin Type V and VI.[2] They concluded that the epidermal H2O2 levels were not increased but rather decreased in patients with NSV contrary to the previous belief.[2]
In another study, melanocytes cultured from patients with vitiligo were found to demonstrate certain changes in their cellular machinery as a result of sustained but sub-lethal oxidative stress.[72] These changes included alterations in the signal-transduction pathways such as mitogen-activated protein kinase hyperactivation and increased sensitivity to apoptosis inducers, as well as increased expression of IL-6, matrix metalloproteinase-3 and insulin-like growth factor-binding protein-3 and −7.[72] Picardo et al.[73] named this conglomerate of cellular changes as ‘senescence phenotype’, because it resembled the cytokine milieu seen in neurodegenerative diseases.
Recent research has pointed out the importance of ‘Nrf2-antioxidant response element (ARE) pathway’ in regulating vitiligo of the skin[74],[75],[76] The Nrf2-ARE is one of the major ROS scavenging pathways that prevent oxidative damage by the induction of downstream antioxidant genes such as heme oxygenase-1 (HO-1).[77] An in vitro study revealed decreased Nrf2 nuclear translocation and transcription in vitiligo melanocytes with resultant decrease in HO-1 expression and aberrant redox balance. In an in vitro study, aspirin was found to dramatically induce NRF2 nuclear translocation and enhance ARE-luciferase activity, thereby inducing the expression of HO-1 in human melanocytes and protecting human melanocytes against H2O2-induced oxidative stress.[77]
A fresh theory unifying the etiological role of oxidative stress and autoimmunity in vitiligo has been proposed, as per which, both the factors coexist in patients with vitiligo but might play different roles in initiation or perpetuation of vitiligo.[78] This theory proposed that in patients with recent onset vitiligo, lipid peroxidation levels, indicative of oxidative stress, were increased while anti-melanocyte antibody levels, indicative of autoimmune process, were increased in patients with long standing vitiligo. Thus, they concluded that oxidative stress plays a pivotal role in initiating vitiligo and the resultant accumulation of ROS damages the melanocytes as well as alters the structure of important melanogenic proteins such as tyrosinase, thereby, making them antigenic. These neoantigens subsequently incite an immune response that sustains the disease process.[78]
Researchers have reported a significant association between a specific polymorphism of forkhead box class O (FOXO) proteins and vitiligo.[79] Decreased levels of FOXO3a protein have been found in patients with active vitiligo which result in impaired antioxidant mechanism causing tissue injury and eventually vitiligo.[79]
Autocytotoxicity
What is known?
Toxic metabolites, both intracellular, such as those formed during melanin synthesis, and extracellular, such as phenols or quinones, may accumulate and damage the melanocytes of genetically susceptible individuals bringing about autocytotoxic injury to the melanocytes. It has been shown that tyrosine upon entering the melaninogenic pathways produces certain electrically unstable by-products, which have the potential to damage other cellular substrates resulting in death of the melanocytes.[80]
Recent updates
In a recent study, Kim et al. investigated the role of high mobility group box 1 (HMGB1) in the pathogenesis of vitiligo.[81] HMGB1 is a non-histone deoxyribonucleic acid (DNA)-binding protein that is secreted from the keratinocytes following exposure to ROS or ultraviolet B (UVB) light. It participates in a number of physiological and pathological processes, including cytokine production, cell proliferation, angiogenesis, cellular differentiation and cell death. In this study, Kim et al. treated the melanocytes with recombinant HMGB1 (rHMGB1) and studied its effects on melanocyte survival.[81] They found that rHMGB1 increased the expression of cleaved caspase 3 and decreased melanin production as well as the expression of melanogenesis-related molecules in treated melanocytes leading to apoptosis and disappearance of the melanocytes. In the same study, it was found that patients with active vitiligo showed significantly higher blood levels of HMGB1 (vs. healthy controls). In addition, greater expression of HMGB1 was observed in the vitiliginous skin (vs. uninvolved skin). Thus, HMGB1 could initiate autocytotoxic injury to the melanocytes secondary to increased oxidative stress or UV light exposure.[81]
Melanocytorrhagy
What is known?
Theory of melanocytorrhagy proposes that NSV is a primary melanocytorrhagic disorder with altered melanocyte responses to friction which induces their detachment, apoptosis and subsequent transepidermal loss.[82] This theory adequately explains the Koebner’s phenomenon because it proposes that weakly anchored melanocytes upon facing minor friction and/or other stress undergo separation from the basement membrane, migrate upward across the epidermis and are eventually lost to the environment resulting in vitiligo at the sites of trauma.[83]
Kumar et al. found that the melanocytes were poorly attached to Type IV collagen in patients with unstable vitiligo, whereas the attachment was fairly firm in patients with a stable disease.[84] More importantly, they demonstrated that in patients with unstable vitiligo, the dendrites of perilesional melanocytes were small, clubbed and retracted which were unable to adhere melanocytes to the basement membrane and the surrounding keratinocytes, thereby, rendering them more prone to transepidermal loss.[84]
Tenascin, an extracellular matrix molecule that inhibits the adhesion of melanocytes to fibronectin, has been found to be elevated in vitiliginous skin contributing to the loss of melanocytes or ineffective repopulation.[85] This results in focal gaps and impaired formation of basement membrane resulting in weakening of the basal attachment of melanocytes and subsequent chronic melanocyte loss known as melanocytorrhagy.[85] It has been proposed that during their transepidermal migration, damaged melanocytes could induce an immune response, thereby, perpetuating vitiligo.[85]
Recent updates
In a recent study by Kumar et al., alterations in the nuclear receptor protein ‘liver X receptor alpha (LXR α)’ was found to play a crucial role in bringing about melanocytorrhagy in patients with NSV. They reported an increased expression of LXR-α, a promoter of apoptosis, in the perilesional skin of patients with NSV.[86] In the same study, treatment with LXR-α agonist, 22(R)-hydroxycholesterol, was found to significantly decrease melanocyte adhesion and proliferation.[86] Thus, they concluded that a higher expression of LXR-α in the melanocytes of the perilesional skin significantly decreased the adhesion and proliferation and increased the apoptosis of melanocytes.
| Deficiency of survival signals | | |
As per this theory, a deficiency of survival signals in the vitiliginous skin leads to apoptosis of melanocytes. In the normal epidermis, stem cell factors released from the neighbouring keratinocytes regulate melanocyte growth and survival by binding to membrane tyrosine kinase receptor c-kit.[87] As such, it is possible that a significantly decreased number of c-kit receptors observed in the perilesional melanocytes[87] and lower expression of stem cell factor from the surrounding keratinocytes[88] may contribute to the death of melanocytes.
Neurohumoral hypothesis: psycho-neuro-endocrine-immune connection in vitiligo
What is known?
There is enough scientific evidence that supports the view that psychological stressors and nervous pathways have an impact on the release of neuropeptides (NPs), various cell behaviours and expression of innate and adaptive immunity in the skin. Evidence in support of the neurohumoral pathogenesis of vitiligo includes common origin of both the melanocytes and nerves from the neural crest cells, the usual presence of SV in a dermatomal fashion, alterations in perspiration and nerve structure in vitiliginous skin and expression of specific neuropeptides in patients with vitiligo.[89],[90] Stress is known to induce the production of various NPs in the skin such as neuropeptide Y (NPY).[91],[92] Immunohistochemical stains have also shown an increase in NPY, both within and around a vitiliginous patch.[93] The release of this neuropeptide from nerve fibres is suspected to initiate a cascade of reactions leading to the destruction of melanocytes, probably, mediated by mast cells and granulocytes.[93] This theory is of major interest when applied to SV. Vitiligo lesions also exhibit increased levels of norepinephrine and low levels of acetylcholine esterase activity.[94],[95] An increased level of neurotransmitters may be directly cytotoxic to cells or may have an indirect effect by causing constriction of supplying blood vessels, thereby causing hypoxia and subsequently cell death.[92],[93] Increased levels of homovanillic and vanillylmandelic acids in the 24-hour urine samples of patients with recent onset or progressive disease support the role of stress and the resultant increase in levels of catecholamines in initiating and perpetuating vitiligo.[92]
Recent updates
Lately, Shaker et al. estimated the gene expression of corticotropin releasing hormone (CRH) and corticotropin releasing hormone receptor 1 (CRHR 1) in both the lesional and non-lesional skin in a sample of patients with vitiligo and assessed its association with psychological stress as measured by the social readjustment stress scale.[96] They found a significant increase in the expression of CRH and CRHR-1 in both the lesional and non-lesional skin of patients with vitiligo and a significant direct association with stress.[96]
Normally, CRH-R1 is known to increase the expression of proopiomelanocortin (POMC) and induce the production of adrenocorticotrophic hormone through the activation of cyclic adenosine monophosphate-dependent pathway(s) in an attempt to bring about increased pigmentation.[97] In addition, the melanocytes respond with enhanced production of cortisol and corticosterone, which is dependent upon POMC activity, to suppress an immune response.[97] Thus, the aforementioned study, shows that the upregulation of CRH and CRHR-1 might be a form of systemic compensation in patients with vitiligo so as to restore normal pigmentation in vitiligo lesions, however, a defective melanogenesis pathway in vitiligo lesions might still lead to failure of repigmentation.
Vitamin D deficiency
What is known?
1,25-dihydroxyvitamin D3 or vitamin D is a fat-soluble vitamin, which is obtained by humans through diet and is synthesized in the skin from 7-dehydrocholesterol under the influence of UV light. It regulates calcium and bone metabolism, controls cell proliferation and differentiation and exerts immunoregulatory activities.[98]
Vitamin D has a nuclear receptor called vitamin D receptor (VDR). VDRs are present in the cells involved in calcium and bone metabolism, and also in the keratinocytes, melanocytes, fibroblasts and immune system cells of the skin.[98] Vitamin D exerts a significant effect on the melanocytes and keratinocytes via various mechanisms. In vitro studies have shown that vitamin D3 increases melanogenesis and tyrosinase content of cultured human melanocytes and protects the melanocytes from UVB-induced apoptosis, thus, contributing to repigmentation in vitiligo macules.[98],[99] Evidence supporting the role of vitamin D in inducing repigmentation in vitiligo skin comes from various studies in which vitamin D analogues, including calcipotriol and tacalcitol, have been shown to enhance repigmentation in patients with vitiligo.[100],[101],[102] In addition, vitamin D has been shown to exert immunomodulatory effects by suppressing the levels of proinflammatory cytokines such as IL-6, IL-8, tumour necrosis factor (TNF)-α and TNF-γ.[103]
Recent updates
In a recent investigation by Ustun et al., insufficient (<30 ng/ml) or very low (<15 ng/ml) levels of vitamin D were observed in majority of patients, although the difference was not significant when 41 control patients were compared to 25 patients with vitiligo.[104] Another study investigated 40 patients with vitiligo and 40 age- and gender-matched controls wherein significantly lower serum vitamin D levels were seen in the patients in relation to the controls.[105]
In a recent systematic review and meta-analyses by Upala et al., it was concluded that a significantly lower concentration of serum 25-hydroxyvitamin D was seen in patients with vitiligo compared with healthy controls.[106]
The following reasons have been theorized behind decreased vitamin D levels in vitiligo patients: (i) consumption of vitamin D in the autoimmune process and (ii) decreased sun exposure by patients in an attempt to prevent sunburn. The former was supported by a study by Saleh et al., who found that patients with vitiligo and autoimmune diseases have lower serum 25(OH)D levels than patients with vitiligo without autoimmune diseases, though, the difference was not statistically significant.[105]
On the contrary, recent studies by Karagün et al.,[107] Karagüzel et al.,[108] and Khurrum et al.,[109] could not find any statistically significant difference in vitamin D levels between patients and healthy controls. Nonetheless, Karagüzel et al. concluded that after six months of treatment, lesion size decreased in patients who received combination treatment with topical tacrolimus 0.1% and vitamin D daily (P < 0.001); while the lesion size increased in patients who received only topical therapy (P < 0.01), thereby, substantiating the role of vitamin D supplementation in patients with vitiligo.[108]
Hyperhomocystinemia
What is known?
Vitamin B12 and folic acid are important cofactors required by the enzyme homocysteine (Hcy) methyltransferase for the regeneration of methionine from Hcy in the activated methyl cycle.[110] Consequently, a nutritional deficiency in either of these two vitamins results in an increase in Hcy levels and a decrease in methionine levels in the circulation.[111],[112] Reduced levels of vitamin B12 and folic acid have been reported in patients with vitiligo.[113],[114],[115] Moreover, it has been noted that homocystinuria is associated with fair skin and hair, a phenomenon often described as ‘pigmentary dilution’.[116]
Low CAT activity is detected in patients with vitiligo, which is known to affect Hcy metabolism.[117] In addition, it has been suggested that an increase in local Hcy levels interferes with normal melanogenesis and plays a role in the pathogenesis of vitiligo by inhibiting the action of histidase and tyrosinase enzymes in the skin.[118] In a pilot study by Shaker and El-Tahlawi, involving 26 patients with vitiligo, it was found that the mean serum Hcy level in the patient group was significantly higher than in the control group (P < 0.001).[119] The mean Hcy level in patients with progressive disease was significantly higher than those in the control group (P < 0.001). In patients with stable disease, the mean Hcy level was higher, but not significantly, (P > 0.05), whereas in patients with regressive disease, the mean Hcy level was almost the same as that of the controls (P > 0.05).[119]
Several theories back up the possible effects of elevated Hcy on melanocytes in vitiliginous skin. (i) The production of toxic ROS by Hcy oxidation adds to the oxidative stress in vitiligo that may contribute to the destruction of the melanocytes in vitiligo skin.[120],[121] The fact that folic acid has an antioxidant effect in vitiligo backs up this hypothesis.[122] (ii) Hcy inhibits tyrosinase enzyme probably by interacting with copper at the active site of the enzyme.[123] (iii) Other harmful effects of homocysteinemia may be due to the reaction of Hcy with proteins forming disulphides and the conversion of Hcy to highly reactive thiolactone, which could react with the proteins forming NH–CO– adducts, thus, affecting the body’s proteins and enzymes.[124] However, some researchers did not find a significant difference in levels between patients with vitiligo and controls.[125],[126]
Recent updates
In the recent years, there was a surge of studies that supported the role of elevated levels of Hcy in the etiopathogenesis of vitligo.[127],[128],[129],[130] However, the major drawback of all the studies discussed so far was that they were performed on a small number of participants. Finally, Alghamdi et al.[130] and Chen et al.[131] published large studies, which included 306 and 2000 participants, respectively. Alghamadi et al. included 153 patients with vitiligo and 153 age- and sex-matched healthy controls and recorded that Hcy and vitamin B12 levels were not significantly different in patients with vitiligo from those in healthy controls.[130] Chen et al. conducted a study involving 1000 patients with vitiligo and 1000 age- and sex-matched controls and found that patients with vitiligo had higher levels of serum Hcy as well as lower activity concentrations of methylenetetrahydrofolate reductase (MTHFR) gene than the controls.[131] Thus, the findings of these two large studies further added to the conflict. In a recent study, Anbar et al., found significantly increased Hcy level in patients’ lesional-induced bulla, although no differences were seen in the serum levels between the cases and the controls.[132] They suggested the possibility that Hcy is produced locally in the lesions, and as such, needs a larger lesional surface area to have a detectable level in the serum. Thus, they concluded that larger the surface area affected higher the serum Hcy levels. This reinforced the conclusions drawn by Silverberg and Silverberg, who reported elevated levels of serum Hcy in cases with extensive vitiligo and recommended it as a severity marker on the initial examination of patients with vitiligo.[133] In a recent study conducted in India, serum Hcy levels were found to be higher than the western reference standards in both cases and controls.[134] This could partly be explained by a predominantly vegetarian Indian population included in the study, whose diet is deficient in vitamin B12 and partly by genetic polymorphisms in the MTHFR gene.The authors did not notice any significant difference in the Hcy levels between cases and controls and suggested that serum Hcy may not be a reliable marker in the Indian population probably because of differences in dietary habits.[134]
| Role of tumour necrosis factor alpha | | |
Tumour necrosis factor-alpha (TNF-α) is one of the major cytokines implicated in the pathogenesis of vitiligo. TNF-α has been shown to inhibit melanocyte differentiation from stem cells, hamper melanocyte function and destroy melanocytes through induction of various apoptotic pathways.[135] However, the use of anti-TNF-α agents has been considered to have mixed results. There is increasing data on the occurrence of vitiligo as a side effect of anti-TNF-α therapy used for a variety of autoimmune diseases such as psoriasis or chronic inflammatory rheumatic diseases.[136],[137],[138] On the other hand, TNF-α inhibition has been found to halt disease progression in patients with progressive vitiligo by quashing cell-mediated immunity.[139] These two strikingly different effects of anti TNF-α therapy can be explained by different effects of various anti TNF-α agents on T reg production and activation and on Th1/Th2 cytokine balance. For example, in ankylosing spondylitis infliximab reduces and etanercept enhances IFN-γ production.[139] In addition, the co-occurrence of vitiligo with various inflammatory diseases (including psoriasis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis) is well described, therefore, the development or worsening of skin depigmentation may be coincidental and related to the underlying disease. Thus, it has been suggested that etanercept should be considered the preferred anti-TNF-α agent in patients at risk of developing vitiligo to mitigate the risk of this adverse event during therapy for other conditions.[139]
| The convergence theory | | |
The convergence theory states that all the aforementioned theories, namely genetic, neurohumoral, autocytoxic, autoimmunity, melanocytorrhagy, altered cellular environment and impaired melanocyte migration, each contribute to the pathogenesis of vitiligo and none are mutually exclusive.[140],[141] This theory has been summarized in [Figure 1]. [Table 1] summarizes the various theories implicated in the pathogenesis of vitiligo and Recent updates in each of the proposed theories. | Figure 1: Proposed patho-mechanisms behind the convergence theory. Convergence theory proposes that the various triggers, perhaps, work in combination to bring about onset of vitiligo. (I) Genetic theory: In a genetically predisposed person, various environmental triggers such as UV radiation, stress and ROS bring about the onset of vitiligo. (II) Neurohumoral hypothesis: Stress brings about an increased secretion of catecholamines and neuropeptides leading to increased production of free radicals, which bring about damage to melanocytes and generation of neoantigens, thereby, triggering immune response. (III) Autocytotoxic hypotheses: Exposure to UV radiation leads to spontaneous production of ROS and increased HMGB1 (high-mobility group box 1) protein level, which brings about activation of caspases, and subsequent loss of melanocytes. (IV) Autoimmune hypothesis: Various triggers bring about synthesis of neoantigens, which initiate an autoimmune phenomenon. (V) Melanocytorrhagy: ROS, structural alterations in melanocytes and alterations in tenascin lead to loss of adhesion of melanocytes to the basement membrane which results in transepidermal elimination of melanocytes on exposure to mild trauma
Click here to view |
 | Table 1: A summary of the major theories implicated in the pathogenesis of vitiligo and its Recent updates
Click here to view |
| Conclusion | | |
The cause of vitiligo still remains unknown, although, it is clear that several different pathophysiological processes may be involved. The best-supported hypothesis so far is the autoimmune hypothesis followed by the oxidative stress theory. Newer theories, such as melanocytorrhagy, decreased melanocyte survival and the role of HMGB-1 DNA-binding protein, homocysteine and vitamin D deficiency have recently been put forward. Because all of these theories seem plausible, it is likely that vitiligo may indeed include an array of disorders with different pathophysiological background yet a common phenotype.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond) 2011;120:99-120.  [ PUBMED] |
| 2. | Zailaie MZ. Epidermal hydrogen peroxide is not increased in lesional and non-lesional skin of vitiligo. Arch Dermatol Res 2017;309:31-42. [ PUBMED] |
| 3. | Lu T, Gao T, Wang A, Jin Y, Li Q, Li C. Vitiligo prevalence study in Shaanxi Province, China.Int J Dermatol 2007;46:47-51. [ PUBMED] |
| 4. | Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977;113:47-52. [ PUBMED] |
| 5. | Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 1985;2:71-8. |
| 6. | Dwivedi M, Laddha NC, Shajil EM, Shah BJ, Begum R. The ACE gene I/D polymorphism is not associated with generalized vitiligo susceptibility in Gujarat population. Pigment Cell Melanoma Res 2008;21:407-8. [ PUBMED] |
| 7. | Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011;65:473-91. [ PUBMED] |
| 8. | Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003;16:208-14. [ PUBMED] |
| 9. | Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated. Am J Hum Genet 1994;55:981-90. [ PUBMED] |
| 10. | Majumder PA. Genetics and prevalence of vitiligo vulgaris. In: Hann SK, Nordlund J, editors. Vitiligo: A Monograph on the Basic and Clinical Science. Oxford: Blackwell Science Ltd.; 2000. |
| 11. | Spritz RA. The genetics of generalized vitiligo: Autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med 2010;19;2:78. |
| 12. | Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun 2008;10:244-57. [ PUBMED] |
| 13. | Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci 2005;39:137-46. [ PUBMED] |
| 14. | Liu JB, Li M, Chen H, Zhong SQ, Yang S, Du WD et al. Association of vitiligo with HLA-A2: A meta-analysis. J Eur Acad Dermatol Venereol 2007;21:205-13. |
| 15. | Canton I, Akhtar S, Gavalas NG, Gawkrodger DJ, Blomhoff A, Watson PF et al. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun 2005;6:584-7. |
| 16. | Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:1216-25. |
| 17. | Ren Y, Yang S, Xu S, Gao M, Huang W, Gao T et al. Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet 2009;5:e1000523. |
| 18. | Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M et al. Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3–p32.2. Hum Mol Genet 2002;11:661-7. |
| 19. | Spritz RA, Gowan K, Bennett DC, Fain PR. Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 2004;74:188-91. [ PUBMED] |
| 20. | Wang P, Li Y, Nie H, Zhang X, Shao Q, Hou X et al. The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual. J Dermatol Sci 2016;84:40-9. |
| 21. | Song P, Li K, Liu L, Wang X, Jian Z, Zhang W et al. Genetic polymorphism of the Nrf2 promoter region is associated with vitiligo risk in Han Chinese populations. J Cell Mol Med 2016;20:1840-50. |
| 22. | Šahmatova L, Tankov S, Prans E, Aab A, Hermann H, Reemann P et al. MicroRNA-155 is Dysregulated in the Skin of Patients with Vitiligo and Inhibits Melanogenesis-associated Genes in Melanocytes and Keratinocytes. Acta Derm Venereol 2016;96:742-7. |
| 23. | Traks T, Keermann M, Karelson M, Rätsep R, Reimann E, Silm H et al. Polymorphisms in Toll-like receptor genes are associated with vitiligo. Front Genet 2015;6:278. |
| 24. | Shen C, Gao J, Sheng Y, Dou J, Zhou F, Zheng X et al. Genetic susceptibility to Vitiligo: GWAS approaches for identifying vitiligo susceptibility Genes and Loci. Front Genet 2016;7:3. Published online 2016 Feb 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740779/. doi: 10.3389/fgene.2016.00003. |
| 25. | Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996;148:1219-28. [ PUBMED] |
| 26. | Badri AM, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudie RB. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993;170:149-55. [ PUBMED] |
| 27. | Hann SK, Park YK, Lee KG, Choi EH, Im S. Epidermal changes in active vitiligo. J Dermatol 1992;19:217-22. [ PUBMED] |
| 28. | Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-8. [ PUBMED] |
| 29. | Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001;117:326-32. |
| 30. | Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B et al. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease. Activity and are predominantly directed against MelanA/-MART1. J Invest 2001;116:891-7. |
| 31. | Allard EL, Hardy MP, Leignadier J, Marquis M, Rooney J, Lehoux D et al. Overexpression of IL-21 promotes massive CD8+ memory T cell accumulation. Eur J Immunol 2007;37:3069-77. |
| 32. | Liu S, Lizée G, Lou Y, Liu C, Overwijk WW, Wang G et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol 2007;19:1213-21. |
| 33. | Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-g for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol 2012;132:1869-76. [ PUBMED] |
| 34. | Shi F, Erf GF. IFN-g, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J Invest Dermatol 2012;132:642-9. [ PUBMED] |
| 35. | Singh RK, Lee KM, Vujkovic-Cvijin I, Ucmak D, Farahnik B, Abrouk M et al. The role of IL-17 in vitiligo: A review. Autoimmun Rev 2016;15:397-404. |
| 36. | Zhou L, Shi YL, Li K, Hamzavi I, Gao TW, Huggins RH et al. Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res 2015;28:324-9. |
| 37. | Bhardwaj S, Rani S, Srivastava N, Kumar R, Parsad D. Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo. Cytokine 2017;91:153-61. doi: 10.1016/j.cyto.2016.12.014. [ PUBMED] |
| 38. | Vaccaro M, Cicero F, Mannucci C, Calapai G, Spatari G, Barbuzza O et al. L 33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. Arch Dermatol Res 2016;308:527-30. |
| 39. | Dwivedi M, Kemp EH, Laddha NC, Mansuri MS, Weetman AP, Begum R. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. Autoimmun Rev 2015;14:49-56. [ PUBMED] |
| 40. | Lili Y, Yi W, Ji Y, Yue S, Weimin S, Ming L. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012;7. doi: 10.1371/journal.pone.0037513.e37513. |
| 41. | Dwivedi M, Laddha NC, Arora P, Marfatia YS, Begum R. Decreased regulatory T-cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 2013;26:586-91. [ PUBMED] |
| 42. | Abdallah M, Lotfi R, Othman W, Galal R. Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo. Int J Dermatol 2014;53:940-6. [ PUBMED] |
| 43. | Shi F, Erf GF. IFN-g, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J Invest Dermatol 2012;132:642-9. [ PUBMED] |
| 44. | Khan R, Gupta S, Sharma A. Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo. J Am Acad Dermatol 2012;66:510-1. [ PUBMED] |
| 45. | Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989;7:136-45. |
| 46. | Cui J, Arita Y, Bystryn JC. Characterization of vitiligo antigens. Pigment Cell Res 1995;8:53-9. [ PUBMED] |
| 47. | Norris DA, Capin L, Muglia JJ, Osborn RL, Zerbe GO, Bystryn JC et al. Enhanced susceptibility of melanoctyes to different immunologic effector mechanisms in vitro: Potential mechanisms for postinflammatory hypopigmentation and vitiligo. Pigment Cell Melanoma Res 1988;1:113-23. |
| 48. | Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrud B, Yecheskel G et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996;105:84-8. |
| 49. | Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active specific immunotherapy. J Invest Dermatol 1998;111:1034-9. |
| 50. | Hedstrand H, Ekwall O, Olsson MJ, Landgren E, Kemp EH, Weetman AP et al. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem 2001;276:35390-5. |
| 51. | Zhu MC, Ma HY, Zhan Z, Liu CG, Luo W, Zhao G. Detection of auto antibodies and transplantation of cultured autologous melanocytes for the treatment of vitiligo. Exp Ther Med 2017;13:23-8. [ PUBMED] |
| 52. | Zhu MC, Liu CG, Wang DX, Zhan Z. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo. Genet Mol Res 2015;14:160-73. |
| 53. | Schallreuter KU, Moore J, Wood JM, Beazley WD, Peters EM, Marles LK et al. Epidermal H2O2 accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: Identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol 2001;116:167-74. |
| 54. | Schallreuter KU, Moore J, Wood JM, Behrens-Williams S, Panske A, Harari M et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Invest Dermatol Symp Proc 1999;4:91-6. |
| 55. | Schallreuter KU, Moore J, Behrens-Williams S, Behrens-Williams S, Panske A, Harari M et al. Rapid initiation of repigmentation of vitiligo with dead sea limatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 2002;41:482-7. [ PUBMED] |
| 56. | Dell’Anna ML, Urbanelli S, Mastrofrancesco A, Camera E, Iacovelli P, Leone G et al. Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients. Pigment Cell Res 2003;16:553-9. |
| 57. | Swalwell H, Latimer J, Haywood RM, Birch-Machin MA. Investigating the role of melanin in UVA/UVB- and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells. Free Radic Biol Med 2011;52:626-34. [ PUBMED] |
| 58. | Yildirim M, Baysal V, Inaloz HS, Can M. The role of oxidants and antioxidants in generalized vitiligo at tissue level. J Eur Acad Dermatol Venereol 2004;18:683-6. [ PUBMED] |
| 59. | Latha B, Babu M. The involvement of free radicals in burn injury: A review. Burns 2001;27:309-17. [ PUBMED] |
| 60. | Khan R, Satyam A, Gupta S, Sharma VK, Sharma A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch Dermatol Res 2009;301:731-7. [ PUBMED] |
| 61. | Arican O, Kurutas EB. Oxidative stress in the blood of patients with active localized vitiligo. Acta Dermatovenerol Alp Pannonica Adriat 2008;17:12-6. [ PUBMED] |
| 62. | Sravani PV, Babu NK, Gopal KV, Rao GR, Rao AR, Moorthy B et al. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol 2009;75:268-71. [ PUBMED] [Full text] |
| 63. | Dammak I, Boudaya S, Ben Abdallah F, Turki H, Attia H, Hentati B. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int J Dermatol 2009;48:476-80. [ PUBMED] |
| 64. | Ines D, Sonia B, Riadh BM, Amel el G, Slaheddine M, Hamida T et al. A comparative study of oxidant-antioxidant status in stable and active vitiligo patients. Arch Dermatol Res 2006;298:147-52. |
| 65. | Dammak I, Boudaya S, Ben Abdallah F, Turki H, Attia H, Hentati B. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int J Dermatol 2009;48:476-80. [ PUBMED] |
| 66. | Casp CB, She JX, McCormack WT. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res 2002;15:62-6. [ PUBMED] |
| 67. | Aronoff S. Catalase: Kinetics of photooxidation. Science 1965;150:72-3. [ PUBMED] |
| 68. | Schallreuter KU, Wood JM, Pittelkow MR, Buttner G, Swanson N, Korner C et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996;288:14-8. |
| 69. | Schallreuter KU, Wood JM, Ziegler I, Lemke KR, Pittelkow MR, Lindsey NJ et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994;1226:181-92. |
| 70. | Beazley WD, Gaze D, Panske A, Panzig E, Schallreuter KU. Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br J Dermatol 1999;141:301-3. [ PUBMED] |
| 71. | Westerhof W, Manini P, Napolitano A, D’Ischia M. The haptenation theory of vitiligo and melanoma rejection: A close-up. Exp Dermatol 2011;20:92-6. |
| 72. | Bellei B, Pitisci A, Ottaviani M, Ludovici M, Cota C, Luzi F et al. Vitiligo: A possible model of degenerative diseases. PLoS One 2013;8:e59782. |
| 73. | Picardo M, Dell’Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D et al. Vitiligo. Nat Rev Dis Primers 2015;1:15011. |
| 74. | Qiu L, Song Z, Setaluri V. Oxidative stress and vitiligo: The Nrf2-ARE signaling connection. J Invest Dermatol 2014;134:2074-6. [ PUBMED] |
| 75. | Jian Z, Li K, Liu L, Zhang Y, Zhou Z, Li C et al. Heme oxygenase-1 protects human melanocytes from H2O2-induced oxidative stress via the Nrf2-ARE pathway. J Invest Dermatol 2011;131:1420-7. |
| 76. | Jian Z, Li K, Song P, Zhu G, Zhu L, Cui T et al. Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: A possible mechanism for melanocyte degeneration in vitiligo. J Invest Dermatol 2014;134:2221-30. |
| 77. | Jian Z, Tang L, Yi X, Liu B, Zhang Q, Zhu G et al. Aspirin induces Nrf2-mediated transcriptional activation of haem oxygenase-1 in protection of human melanocytes from H2O2-induced oxidative stress. J Cell Mol Med 2016;20:1307-18. |
| 78. | Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol 2014;23:352-3. |
| 79. | Ozel Turkcu U, Solak Tekin N, Gokdogan Edgunlu T, Karakas Celik S, Oner S. The association of FOXO3A gene polymorphisms with serum FOXO3A levels and oxidative stress markers in vitiligo patients. Gene 2014;536:129-34. [ PUBMED] |
| 80. | Hann SK, Chun W. Autocytotoxic hypothesis for the destruction of melanocytes as the cause of vitiligo. In: Hann SK, Nordlund J, editors. Vitiligo. Oxford: Blackwell Science Ltd.; 2000. |
| 81. | Kim JY, Lee EJ, Seo J, Oh SH. Impact of HMGB1 on melanocytic survival and its involvement in the pathogenesis of vitiligo. Br J Dermatol 2017;176:1558-68. doi: 10.1111/bjd.15151. [ PUBMED] |
| 82. | Kumar R, Parsad D. Melanocytorrhagy and apoptosis in vitiligo: Connecting jigsaw pieces. Indian J Dermatol Venereol Leprol 2012;78:19-23. [ PUBMED] [Full text] |
| 83. | Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-32. |
| 84. | Kumar R, Parsad D, Kanwar AJ. Role of apoptosis and melanocytorrhagy: A comparative study of melanocytes adhesion in stable and unstable vitiligo. Br J Dermatol 2011;164:187-91. [ PUBMED] |
| 85. | Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol 1997;137:171-8. [ PUBMED] |
| 86. | Kumar R, Parsad D, Kanwar AJ, Kaul D. Altered levels of LXR-a: Crucial implications in the pathogenesis of vitiligo. Exp Dermatol 2012;21:853-8. [ PUBMED] |
| 87. | Kitamura R, Tsukamoto K, Harada K, Shimizu A, Shimada S, Kobayashi T et al. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: Role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol 2004;202:463-75. |
| 88. | Lee AY, Kim NH, Choi WI, Youm YH. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. J Invest Dermatol 2005;124:976-83. [ PUBMED] |
| 89. | Lotti T, Zanardelli M, D’Erme AM. Vitiligo: What’s new in the psycho-neuro-endocrine-immune connection and related treatments. Wien Med Wochenschr 2014;164:278-85. |
| 90. | Orecchia GE. Neural pathogenesis. In: Hann S, Nordlund J, editors. Vitiligo. Oxford: Blackwell Science Ltd.; 2000. |
| 91. | Al’Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-5. |
| 92. | Morrone A, Picardo M, de Luca C, Terminali O, Passi S, Ippolito F. Catecholamines and vitiligo. Pigment Cell Res 1992;5:65-9. [ PUBMED] |
| 93. | Le Poole IC, van den Wijngaard RM, Smit NP, Oosting J, Westerhof W, Pavel S. Catechol-O-methyltransferase in vitiligo. Arch Dermatol Res 1994;286:81-6. [ PUBMED] |
| 94. | Schallreuter KU, Wood JM, Pittelkow MR, Buttner G, Swanson N, Korner C et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996;288:14-8. |
| 95. | Iyengar B. Modulation of melanocytic activity by acetylcholine. Acta Anat 1989;136:139-41. [ PUBMED] |
| 96. | Shaker OG, Eltahlawi SM, Tawfic SO, Eltawdy AM, Bedair NI. Corticotropin-releasing hormone (CRH) and CRH receptor 1 gene expression in vitiligo. Clin Exp Dermatol 2016;41:734-40. [ PUBMED] |
| 97. | Slominski A, Zmijewski M, Zbytek B, Tobin DJ, Theoharides TC, Rivier J et al. Key role of CRF in the skin stress response system. Endocrine Rev 2013;34:827-84. |
| 98. | Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4-8. [ PUBMED] |
| 99. | Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008;4:404-12. [ PUBMED] |
| 100. | Birlea SA, Costin GE, Norri DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev 2009;29:514-46. |
| 101. | Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998;197:167-70. [ PUBMED] |
| 102. | Oh SH, Kim T, Jee H, Do JE, Lee JH. Combination treatment of non-segmental vitiligo with a 308-nm xenon chloride excimerlaser and topical high-concentration tacalcitol: A prospective, single-blinded, paired, comparative study. J Am Acad Dermatol 2011;65:428-30. [ PUBMED] |
| 103. | Koizumi H, Kaplan A, Shimizu T, Ohkawara A. 1,25-Dihydroxyvitamin D3 and a new analogue, 22-oxacalcitriol, modulate proliferation and interleukin-8 secretion of normal human keratinocytes. J Dermatol Sci 1997;15:207-13. [ PUBMED] |
| 104. | Ustun I, Seraslan G, Gokce C, Motor S, Can Y, Ugur Inan M et al. Investigation of vitamin D levels in patients with vitiligo vulgaris. Acta Dermatovenerol Croat 2014;22:110-3. |
| 105. | Saleh HM, Abdel Fattah NS, Hamza HT. Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. Photodermatol Photoimmunol Photomed 2013;29:34-40. [ PUBMED] |
| 106. | Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: A systematic review and meta-analysis. Photodermatol Photoimmunol Photomed 2016;32:181-90. |
| 107. | Karagün E, Ergin C, Baysak S, Erden G, Aktaş H, Ekiz Ö. The role of serum vitamin D levels in vitiligo. Postepy Dermatol Alergol 2016;33:300-2. |
| 108. | Karagüzel G, Sakarya NP, Bahadır S, Yaman S, Ökten A. Vitamin D status and the effects of oral vitamin D treatment in children with vitiligo: A prospective study. Clin Nutr ESPEN 2016;15:28-31. |
| 109. | Khurrum H, AlGhamdi KM. The relationship between the serum level of vitamin D and vitiligo: A controlled study on 300 subjects. J Cutan Med Surg 2016;20:139-45. [ PUBMED] |
| 110. | Mudd SH, Levy HL, Skorby LF. Disorders of transsulfuration. In: Scriver CR, Beudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. 7th ed. New York: McGraw-Hill; 1995. p. 1279-327. |
| 111. | Guttormsen AB, Schneede J, Ueland PM, Refsum H. Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am J Clin Nutr 1996;64:194-202. |
| 112. | Minet JC, Bissé E, Aebischer CP, Beil A, Wieland H, Lütschg J. Assessment of vitamin B12, folate and vitamin B6 status and relation to sulfur amino acid metabolism in neonates. Am J Clin Nutr 2000;72:751-7. |
| 113. | Montes LF, Dias ML, Lajous J, Garcia NJ. Folic acid and vitamin B12 in vitiligo: A nutritional approach. Cutis 1992;50:39-42. |
| 114. | Kim SM. Serum levels of folic acid and vitamin B12 in Korean patients with vitiligo. Yonsei Med J 1999;40:195-8. |
| 115. | El-Batawi MM, El-Tawil NE, El-Tawil AE. Serum levels of vitamin B12 and folic acid in Egyptian patients with vitiligo. Egypt J Derm Androl 2001;21:77-80. |
| 116. | Brenton DP, Cusworth DC, Dent CE, Jones EE. Homocystinuria. Clinical and dietary studies.Q J Med 1966;35:325-46. [ PUBMED] |
| 117. | Goth L, Rass P, Pay A. Catalase enzyme mutations and their association with diseases. Mol Diagn 2004;8:141-9. |
| 118. | Kurbanov Kh, Burobin VA, Berezov TT. Histidase activity of the skin in relation to the state of melanogenesis. Bull Exp Biol Med 1974;78:898-900. |
| 119. | Shaker OG, El-Tahlawi SM. Is there a relationship between homocysteine and vitiligo? A pilot study. Br J Dermatol 2008;159:720-4. [ PUBMED] |
| 120. | Guilland JC, Favier A, Potier de Courcy G, Galan P, Hercberg S. Hyperhomocysteinemia: An independent risk factor or a simple marker of vascular disease? 1. Basic data. Pathol Biol (Paris) 2003;51:101-10. [In French]. |
| 121. | Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. New York: Mosby; 2003. p. 947-73. |
| 122. | Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr 2000;72:315-23. |
| 123. | Reish O, Townsend D, Berry SA, Tsai MY, King RA. Tyrosinase inhibition due to interaction of homocyst(e)ine with copper: The mechanism for reversible hypopigmentation in homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1995;57:127-32. [ PUBMED] |
| 124. | Ramakrishnan S, Sulochana KN, Lakshmi S, Selvi R, Angayarkanni N. Biochemistry of homocysteine in health and diseases. Indian J Biochem Biophys 2006;43:275-83. [ PUBMED] |
| 125. | Balci DD, Yonden Z, Yenin JZ, Okumus N. Serum homocysteine, folic acid and vitamin B12 levels in vitiligo. Eur J Dermatol 2009;19:382-3. [ PUBMED] |
| 126. | Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin B12, folic acid levels and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism in vitiligo. Dis Markers 2012;33:85-9. [ PUBMED] |
| 127. | Singh S, Singh U, Pandey SS. Increased level of serum homocysteine in vitiligo. J Clin Lab Anal 2011;25:110-2. [ PUBMED] |
| 128. | Karadag AS, Tutal E, Ertugrul DT, Akin KO, Bilgili SG. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin Exp Dermatol 2012;37:62-4. [ PUBMED] |
| 129. | Ataş H, Cemil BÇ, Gönül M, Baştürk E, Çiçek E. Serum levels of homocysteine, folate and vitamin B12 in patients with vitiligo before and after treatment with narrow band ultraviolet B phototherapy and in a group of controls. J Photochem Photobiol B 2015;148:174-80. |
| 130. | Alghamdi KM, Moussa Na KM, Huma K. Is there a real relationship between serum level of homocysteine and vitiligo? A controlled study on 306 subjects. J Cutan Med Surg 2014;18:5-7. |
| 131. | Chen JX, Shi Q, Wang XW, Guo S, Dai W, Li K et al. Genetic polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR) and risk of vitiligo in Han Chinese population: A genotype-phenotype correlation study. Br J Dermatol 2014;170:1092-9. |
| 132. | Anbar T, Zuel-Fakkar NM, Matta MF, Arbab MM. Elevated homocysteine levels in suction-induced blister fluid of active vitiligo lesions. Eur J Dermatol 2016;26:64-7. [ PUBMED] |
| 133. | Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of vitiligo vulgaris severity: A pilot study. J Am Acad Dermatol 2011;64:445-7. [ PUBMED] |
| 134. | Gupta S, D’souza P, Dhali TK, Arora S. Serum homocysteine and total antioxidant status in vitiligo: A case control study in Indian population. Indian J Dermatol 2016;61:131-6. [ PUBMED] [Full text] |
| 135. | Toussirot É, Aubin F. Paradoxical reactions under TNF-a blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview. RMD Open 2016;2:e000239. doi: 10.1136/rmdopen-2015-000239. |
| 136. | Ramírez-Hernández M, Marras C, Martínez-Escribano JA. Infliximab-induced vitiligo. Dermatology 2005;210:79-80. |
| 137. | Toussirot E, Salard D, Algros MP, Aubin F. Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab. Ann Dermatol Venereol 2013;140:801-2. [ PUBMED] |
| 138. | Posada C, Flórez A, Batalla A, Alcázar JJ, Carpio D. Vitiligo during treatment of Crohn’s disease with adalimumab: Adverse effect or co-occurrence? Case Rep Dermatol 2011;3:28-31. |
| 139. | Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW et al. Tumour necrosis factor-a inhibition can stabilize disease in progressive vitiligo. Br J Dermatol 2015;173:641-50. |
| 140. | Namazi MR. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: Can they be interconnected? Pigment Cell Res 2007;20;360-3. |
| 141. | Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: A convergence theory. Exp Dermatol 1993;2:145-53. [ PUBMED] |
[Figure 1]
[Table 1]
| This article has been cited by | | 1 |
Biologic and targeted therapeutics in vitiligo |
|
| Priyanka Karagaiah, Robert A. Schwartz, Torello Lotti, Uwe Wollina, Stephan Grabbe, Mohamad Goldust | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 2 |
The role of cytokines and vitamin D in vitiligo pathogenesis |
|
| Amir Mohammad Beyzaee, Mohamad Goldust, Anant Patil, Ghasem Rahmatpour Rokni, Samira Beyzaee | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 3 |
Melan-A expression related to apoptosis of melanocytes in segmental and non-segmental vitiligo |
|
| Boedhy Setyanto, Handono Kalim, Sri Poeranto, Dhelya Widasmara | | F1000Research. 2022; 11: 1211 | | [Pubmed] | [DOI] | | | 4 |
Modalitas Terapi Vitiligo Pada Anak |
|
| Nathania Amelinda, Endra Yustin Ellistasari, Indah Julianto | | MEDICINUS. 2022; 35(3): 37 | | [Pubmed] | [DOI] | | | 5 |
Vitamin D and immunomodulation in the skin: a useful affirmative nexus |
|
| Saptadip Samanta | | Exploration of Immunology. 2021; | | [Pubmed] | [DOI] | | | 6 |
Efficacy of topical 5% 5-fluorouracil with needling versus 5% 5-fluorouracil alone in stable vitiligo: A randomized controlled study |
|
| FatimaT Zahra,Mohammad Adil,SyedS Amin,Mohd Mohtashim,Roopal Bansal,HaniaQ Khan | | Journal of Cutaneous and Aesthetic Surgery. 2020; 13(3): 197 | | [Pubmed] | [DOI] | | | 7 |
Emerging drugs for the treatment of vitiligo |
|
| Priyanka Karagaiah,Yan Valle,Julia Sigova,Nicola Zerbinati,Petar Vojvodic,Davinder Parsad,Robert A. Schwartz,Stephan Grabbe,Mohamad Goldust,Torello Lotti | | Expert Opinion on Emerging Drugs. 2020; 25(1): 7 | | [Pubmed] | [DOI] | | | 8 |
Predominant role of innate pro-inflammatory cytokines in vitiligo disease |
|
| Nasser Gholijani,Mohammad-Reza Yazdani,Ladan Dastgheib | | Archives of Dermatological Research. 2019; | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for